AtriCure (ATRC) FDA Approvals $28.29 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$28.30 +0.01 (+0.04%) As of 05/22/2026 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock AtriCure's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by AtriCure (ATRC). Over the past two years, AtriCure has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as LeAAPS. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. LeAAPS FDA Regulatory Events LeAAPS is a drug developed by AtriCure for the following indication: For Stroke Prevention. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Enrollment Completion - July 15,2025Enrollment Completion Drug: LeAAPSAnnounced Date: July 15, 2025Indication: For Stroke PreventionAnnouncementAtriCure, Inc announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally.AI SummaryAtriCure, Inc announced the completion of enrollment in its LeAAPS clinical trial (NCT05478304), a major step toward understanding how to prevent strokes in cardiac surgery patients without a prior Afib diagnosis. Launched in January 2023, the trial successfully enrolled 6,500 patients at 137 centers worldwide, making it one of the largest studies of its kind. The trial is designed to evaluate the AtriClip device’s ability to reduce the risk of ischemic stroke and systemic arterial embolism in high-risk patients undergoing planned cardiac surgery. With plans for five years of follow-up, the study aims to provide clear evidence that could shape future treatment guidelines and improve long-term patient outcomes in a large, often underserved, cardiac surgery population.Read Announcement AtriCure FDA Events - Frequently Asked Questions Has AtriCure received FDA approval? As of now, AtriCure (ATRC) has not received any FDA approvals for its therapy in the last two years. What drugs has AtriCure submitted to the FDA? In the past two years, AtriCure (ATRC) has reported FDA regulatory activity for LeAAPS. What is the most recent FDA event for AtriCure? The most recent FDA-related event for AtriCure occurred on July 15, 2025, involving LeAAPS. The update was categorized as "Enrollment Completion," with the company reporting: "AtriCure, Inc announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally." What conditions do AtriCure's current drugs treat? Currently, AtriCure has one therapy (LeAAPS) targeting the following condition: For Stroke Prevention. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Axsome Therapeutics FDA EventsBriacell Therap FDA EventsCullinan Therapeutics FDA EventsClimb Bio FDA EventsCorbus Pharmaceuticals FDA EventsDyne Therapeutics FDA EventsEditas Medicine FDA EventsJade Biosciences FDA EventsKura Oncology FDA EventsNovogen FDA EventsOlema Pharmaceuticals FDA EventsPersonalis FDA EventsTG Therapeutics FDA EventsEli Lilly and Company FDA EventsAC Immune FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Teleflex FDA Events AngioDynamics FDA Events Abbott Laboratories FDA Events Medtronic FDA Events Boston Scientific FDA Events Becton, Dickinson and Company FDA Events DexCom FDA Events Insulet FDA Events Haemonetics FDA Events Capricor Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:ATRC last updated on 7/15/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThree companies about to leapfrog Nvidia [And transform the entire industry]Futurist George Gilder - who predicted the smartphone years before the iPhone launched - believes today's AI d...Eagle Publishing | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | SponsoredSkip the Line Opportunity: The SpaceX IPOFormer tech executive and angel investor Jeff Brown - who identified Bitcoin, Tesla, and Nvidia before their h...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AtriCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AtriCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Enrollment Completion - July 15,2025Enrollment Completion Drug: LeAAPSAnnounced Date: July 15, 2025Indication: For Stroke PreventionAnnouncementAtriCure, Inc announced the completion of enrollment in the left atrial appendage exclusion for prophylactic stroke reduction (LeAAPS) clinical trial (NCT05478304). Initiated in January 2023, LeAAPS enrolled 6,500 patients across 137 centers globally.AI SummaryAtriCure, Inc announced the completion of enrollment in its LeAAPS clinical trial (NCT05478304), a major step toward understanding how to prevent strokes in cardiac surgery patients without a prior Afib diagnosis. Launched in January 2023, the trial successfully enrolled 6,500 patients at 137 centers worldwide, making it one of the largest studies of its kind. The trial is designed to evaluate the AtriClip device’s ability to reduce the risk of ischemic stroke and systemic arterial embolism in high-risk patients undergoing planned cardiac surgery. With plans for five years of follow-up, the study aims to provide clear evidence that could shape future treatment guidelines and improve long-term patient outcomes in a large, often underserved, cardiac surgery population.Read Announcement
